EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

Clinical trials

Sunday 02 Jun, 15:00 PM - 16:30 PM Valencia, Spain
Artificial intelligence and Data science Hub Oral Abstract Session on Clinical Trials
Comparative phase 2 bioavailability study of a fast acting, dry powder-based, epinephrine intra-nasal formulation, FMXIN002, for anaphylaxis
Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial
Long-Term Efficacy and Safety of Stapokibart in Patients with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Pivotal Phase 3 Trial
Identifying KIT D816V Mutation in Patients With Evidence of Systemic Mast Cell Activation (MCA) and Enriched for Hereditary Alpha-tryptasemia (HaT): Results From the PROSPECTOR Clinical Trial
Garadacimab improves quality of life in patients with hereditary angioedema: Results from the Phase 3 open-label extension study
A Study Conducted in the Environmental Exposure Chamber (EEC) to Assess Onset of Action of Combination of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Dymista) in the Treatment of Allergic Rhinitis Symptoms Compared to Placebo